Wednesday, 16 May 2018

Ceisteanna (138)

Seán Barrett


138. Deputy Seán Barrett asked the Minister for Health the reason patients with multiple sclerosis have to wait an average of 348 days for a treatment drug to be approved for public funding and in some cases even longer; and if he will make a statement on the matter. [21569/18]

Amharc ar fhreagra

Freagraí scríofa (Ceist ar Health)

The HSE has statutory responsibility for medicine pricing and reimbursement decisions, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. As Minister for Health, I do not have any statutory power or function in relation to the reimbursement of medicines. The Act specifies the criteria for decisions on the reimbursement of medicines.

Under the 2013 Act, if a company would like a medicine to be reimbursed by the HSE in the community drug schemes, it must submit an application to the HSE to have the medicine added to the Reimbursement List.

As outlined in the 2016 Framework Agreement with industry, and in line with the 2013 Act, the HSE will decide, within 180 days of receiving the application (or a longer period if further information is sought from the company), to add the medicine to the reimbursement list, agree to reimburse it as a hospital medicine or refuse to reimburse it.

HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds, on the advice of the National Centre for Pharmacoeconomics (NCPE).

The NCPE conducts health technology assessments for the HSE and makes recommendations on reimbursement to assist HSE decisions. The NCPE uses a decision framework to systematically assess whether a drug is cost-effective as a health intervention.

The HSE strives to reach a decision in as timely a manner as possible. However, because of the significant monies involved, it must ensure that the best price is achieved, as these commitments may be ongoing multi-million euro investments. Price discussions can lead to a protracted deliberation process.

I am keen to engage with industry and to explore ways in which new medicines might be more easily introduced in Ireland. However, any innovative approaches that may be tabled must be compatible with the statutory provisions in place and must also recognise fundamental pricing/funding issues, in the context of finite Exchequer resources.